Trials / Active Not Recruiting
Active Not RecruitingNCT05559931
Single and Repeat Doses of DMT in Healthy Subjects
A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of Ascending Single and Fixed Repeat Intravenous Doses of DMT in Healthy Subjects
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Algernon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study aims to assess the safety and tolerability of single ascending, and fixed repeated doses of N,N-Dimethyltryptamine (DMT) in healthy subjects, when given by intravenous (IV) infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N,N-Dimethyltryptamine | IV infusion over 6 hours |
| DRUG | Placebo | Placebo infusion over 6 hours |
Timeline
- Start date
- 2023-01-13
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2022-09-29
- Last updated
- 2025-01-28
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05559931. Inclusion in this directory is not an endorsement.